NEVRALCAR DUO

NEVRALCAR DUO

60 modified-release swallowable tablets

Nevralcar Duo is a Food Supplement containing Acetyl L-Carnitine, β-caryophyllene from Cloves and Citicoline. The effective dosage corresponding to 1,180 mg of Acetyl-L-Carnitine HCl allows for a specific Neurotrophic, Analgesic and Antioxidant Action.

The Synergy of the 2 Active Ingredients allow pain control in all those clinical situations characterized by Neuropathy of both joint and metabolic origin.

Description

Nevralcar DUO is a Food Supplement in modified-release tablets containing Acetyl L-Carnitine, β-caryophyllene from Cloves and Citicoline, useful to counterbalance a lack of these ingredients.

INGREDIENTS: Acetyl L-Carnitine Hydrochloride; Anti-caking agent: Fatty acids; Citicoline sodium salt; Bulking agent: Microcrystalline cellulose (cellulose gel); Clove (Syzygium aromaticum (L.) Merr. et L.M.Perry, aetheroleum) powder extract titrated 8% in β-caryophyllene; Anti-caking agents: Magnesium hydroxide, Silicon dioxide, Magnesium salts of fatty acids; Colour: Iron oxides; Anti-caking agent: Cross-linked sodium carboxymethyl cellulose; Glazing agent: Hydroxypropyl cellulose; Anti-caking agent: Talc; Glazing agent: Carnauba wax.

Pharmaceutical form

Tablets - Pack of 60 tablets of 1.15 g each. - Gluten Free.

Application

We recommend taking 2 tablets a day with plenty of water, preferably on an empty stomach.

Information / Warnings

WARNINGS: Food Supplements are not intended as a substitute for a varied and balanced diet and healthy lifestyle. Do not exceed the recommended daily dose. Keep out of reach of children under 3 years of age. Do not take in case of hypersensitivity or allergy to one or more components. The product is not suitable for consumption by children.
STORAGE CONDITIONS: Store in a cool and dry place away from light, localized heat sources and sunlight. Avoid contact with water and keep at a temperature below 25°C. The best before date refers to the Product properly stored in unopened package.

Nutritional table

Average contentsfor 2 tablets
Acetyl L-Carnitine Hydrochloride
of which Acetyl L-Carnitine
1180 mg
1000 mg
Clove powder extract
of which β-caryophyllene
125 mg
10 mg
Citicoline250 mg

The information and images on this page may not be up to date; always refer to the product packaging for instructions, directions for use and warnings.

You may also be interested in:

River Pharma products represent progress for the Medical-Scientific Community, as well as the response to the most widespread ailments and diseases in the world.

SYALOX 300 PLUS

SYALOX 300 PLUS

Syalox 300 Plus is indicated in all clinical situations characterised by joint pain and reduced mobility.

Discover the product
NEVRALCAR DUO

NEVRALCAR DUO

The Synergy of the 2 Active Ingredients allow pain control in all those clinical situations characterized by Neuropathy of both joint and metabolic origin.

Discover the product

River Pharma: Healthcare is Our Passion

Nutraceuticals

State-of-the-art products based on high molecular weight Hyaluronic Acid obtained through bio-fermentation technology and are characterised by their effectiveness proven in five distinct therapeutic areas.

Find out more

Medical Devices

The latest generation of medical devices based on Hyaluronic Acid with a high molecular weight, 2 mil D, to be injected, effective for the treatment and prevention of osteoarticular pathologies linked to ageing and for the treatment of acute trauma. 

Find out more

Dermocosmetics

Products that contain, Hyaluronic Acids with a careful selection of molecular weight, amongst other things and are characterised by their anti-ageing effectiveness.

Find out more

<strong>Science Informs: </strong>The River Pharma Blog

Stay up to date, learn more about the research and insights of the most authoritative members of the International Medical-Scientific Community.

Menopause and osteoporosis: what causes bone loss?

Menopause and osteoporosis: what causes bone loss?

Unfortunately for all women who are in menopause osteoporosis is a sad reality that sooner or later will become increasingly present in their lives, this is even more true in all those who already have a genetic predisposition towards this degenerative bone disease.

Keep reading

Iscriviti alla nostra Newsletter

Il tuo appuntamento con la Scienza non si ferma mai. Registrati e rimani sempre aggiornato sulle notizie, gli approfondimenti, gli studi e le soluzioni terapeutiche più all’avanguardia.